CSL named in Best Employers for Diversity (Forbes). Employee workforce up 7%, with 57% of our employee base female. Achieved 76% employee engagement score, up 2.4 points on prior year. SHARED VALUE. US$8.8 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.
CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. ... With annualized revenue of approximately $430 ...
CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications.
This story features CSL LIMITED. For more info SHARE ANALYSIS: CSL. CSL is highly likely to be looking for other avenues of revenue to meet targets in FY21, given a prospective shortfall in plasma collections.-Plasma collection levels present a risk to the near-term revenue outlook-There are several strategies to deal with a shortfall in plasma
CSL Limited ABN: 99 051 588 348 Appendix 4E Full-year ended 30 June 2018 (Previous corresponding period: Year ended 30 June 2017) Results for Announcement to the Market 2018 2017 US$m US$m Sales revenue 7,587.9 6,615.8 Total other revenues 327.4 331.2 Total revenue and other income 7,915.3 6,947.0
